About Ampersand
Ampersand is a company based in Boston (United States) founded in 2020 by Raffi Afeyan and Noubar Afeyan. It operates as a HealthTech. Ampersand has raised $65 million across 1 funding round from investors including Lilly and Flagship Pioneering. The company has 22 employees as of December 31, 2022. Ampersand has completed 1 acquisition, including AbCheck. Ampersand offers products and services including AND-Body Therapeutics. Ampersand operates in a competitive market with competitors including DNAnexus, Cytel, Metagenomi, Octant and Kinomica, among others.
- Headquarter Boston, United States
- Employees 22 as on 31 Dec, 2022
- Founders Raffi Afeyan, Noubar Afeyan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ampersand Biomedicines
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ampersand
Ampersand offers a comprehensive portfolio of products and services, including AND-Body Therapeutics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Programmable medicines are designed for disease-specific precision targeting.
Unlock access to complete
Funding Insights of Ampersand
Ampersand has successfully raised a total of $65M through 1 strategic funding round. The most recent funding activity was a Series B round of $65 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $65.0M
-
First Round
First Round
(20 Mar 2025)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2025 | Amount | Series B - Ampersand | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ampersand
Ampersand has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly and Flagship Pioneering. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences-focused venture capital firm
|
Founded Year | Domain | Location | |
|
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ampersand
Ampersand has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AbCheck. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of human therapeutic antibodies
|
2009 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Ampersand
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ampersand Comparisons
Competitors of Ampersand
Ampersand operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DNAnexus, Cytel, Metagenomi, Octant and Kinomica, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cloud-based genome informatics and data management are provided.
|
|
| domain | founded_year | HQ Location |
Data analysis and statistical solutions are provided for life sciences.
|
|
| domain | founded_year | HQ Location |
Next-generation gene editing tools are developed for drug enhancement.
|
|
| domain | founded_year | HQ Location |
Human cell interaction platform is provided for drug discovery.
|
|
| domain | founded_year | HQ Location |
Bioinformatics platform for precision medicine development is offered.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ampersand
Frequently Asked Questions about Ampersand
When was Ampersand founded?
Ampersand was founded in 2020 and raised its 1st funding round 5 years after it was founded.
Where is Ampersand located?
Ampersand is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Ampersand?
Jason Gardner is the current CEO of Ampersand.
Is Ampersand a funded company?
Ampersand is a funded company, having raised a total of $65M across 1 funding round to date. The company's 1st funding round was a Series B of $65M, raised on Mar 20, 2025.
How many employees does Ampersand have?
As of Dec 31, 2022, the latest employee count at Ampersand is 22.
What does Ampersand do?
Ampersand Biomedicines is engaged in the development of next-generation modular medicines through its proprietary Address, Navigate, Determine (AND) Platform. These medicines, known as AND-Body Therapeutics, are designed to act precisely at the site of disease, avoiding healthy tissue to minimize side effects. The company operates in the biotechnology sector, addressing challenges in drug development by combining localizing elements and actuators for disease modification. Solutions are enabled by a unique Address Map to identify optimal targets for organs, cells, and diseases, ensuring safer and more effective treatments.
Who are the top competitors of Ampersand?
Ampersand's top competitors include DNAnexus, Cytel and Relation Therapeutics.
What products or services does Ampersand offer?
Ampersand offers AND-Body Therapeutics.
How many acquisitions has Ampersand made?
Ampersand has made 1 acquisition, including AbCheck.
Who are Ampersand's investors?
Ampersand has 2 investors. Key investors include Lilly, and Flagship Pioneering.